• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Three million lives saved in U.S. by COVID vaccines: study


Vaccination program has also prevented more than 18 million hospitalizations, saved $1 trillion in medical costs

In the two years since their development COVID-19 vaccinations have prevented more than 18.5 million hospitalizations in the U.S. and saved more than 3 million lives and $1.15 trillion in medical costs.

Those findings emerge from a recently-released study looking at the impact of the U.S.’s COVID-19 vaccination program on reducing infections, hospitalizations and deaths from the disease. According to the study’s authors, the U.S. has administered more than 655 million doses of vaccine since December 2020, with about 80% of the country’s having gotten at least one dose.

The authors—researchers from the University of Maryland, York University and Yale University—arrived at their findings by developing a computer model of COVID-19 transmission that incorporates factors such as U.S. population demographics and comorbidity prevalence, and age-specific risks of severe health outcomes from contracting the disease. Their research was supported by a grant from The Commonwealth Fund.

They used the model to simulate the pandemic’s trajectory without vaccinations and compared those outcomes to the actual numbers of infections, hospitalizations and deaths that occurred between December 2020 and November 2022, and estimated cost savings based on the averted outcomes.

“The swift development of the vaccine, emergency authorization to distribute widely, and rapid rollout have been instrumental on curbing hospitalization and death, while mitigating socioeconomic repercussions of the pandemic,” they write.

In addition to protection against the original version of COVID, they say, the vaccines have minimized the impact of its variants. OMICRON, in particular, has been milder because of the protection afforded by vaccines.

They add that the study may have underestimated the vaccine’s domestic impact since it did not account for the effect of U.S.-developed vaccines on the disease’s trajectory elsewhere. Their absence could have led to the emergence of more variants or importation of more cases into the U.S.

As of mid-December, the U.S. had recorded 1,084,651 deaths from COVID, according to the Centers for Disease Control and Prevention, and had distributed a total of 926,257,435 vaccine doses. About 69% of the population had received both doses of the vaccine, and 13.5% had gotten a bivalent booster dose.

Related Videos